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Dose-dependent changes in target tissue absorption have important implications for determining the
most defensible approach for developing a cancer-based oral toxicity factor for hexavalent chromium
(CrVI). For example, mouse target tissue absorption per unit dose is an estimated 10-fold lower at the
CrVI dose corresponding to the federal maximum contaminant level (MCL) than at the USEPA draft oral
slope factor (SFo) point of departure dose. This decreasing target tissue absorption as doses decrease to
lower, more environmentally-relevant doses is inconsistent with linear low-dose extrapolation. The
shape of the dose–response curve accounting for this toxicokinetic phenomenon would clearly be non-
linear. Furthermore, these dose-dependent differences in absorption indicate that the magnitude of risk
overestimation by a linear low-dose extrapolation approach (e.g., SFo) increases and is likely to span one
or perhaps more orders of magnitude as it is used to predict risk at progressively lower, more environ-
mentally-relevant doses. An additional apparent implication is that no single SFo can reliably predict risk
across potential environmental doses (e.g., doses corresponding to water concentrations 6 the federal
MCL). A non-linear approach, consistent with available mode of action data, is most scientiﬁcally defen-
sible for derivation of an oral toxicity factor for CrVI-induced carcinogenesis.
 2015 The Author. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
A great deal of recent scientiﬁc debate and research concerns
exactly how and under what conditions hexavalent chromium
(CrVI) is likely to induce cancer following oral exposure (e.g.,
Thompson et al., 2011a, 2011b; McCarroll et al., 2010; USEPA,
2010). The mode of action (MOA) for CrVI-induced carcinogenicity
is a primary topic of debate since it typically determines whether
the excess risk observed at very high mouse study oral doses of
CrVI is assumed to extrapolate downward to signiﬁcantly lower,
truly environmentally-relevant human doses in a linear manner
or if a non-linear/threshold dose–response should be expected at
such low doses. More speciﬁc topics of debate include the roles
of mutagenicity and chronic hyperplasia in CrVI-induced carcino-
genicity in target tissues, if gastrointestinal (GI) extracellular
reductive capacity likely imparts a non-linear/threshold character
to the dose–response, and the potential that mouse oral doses in
NTP (2008) exceeded the extracellular CrVI reductive capacity of
the GI tract. Indeed, the CrVI MOA research project (e.g.,
Thompson et al., 2011a) reports that stomach reducing capacitywas likely exceeded at doses causing cancer in the mouse small
intestine based on CrVI intake per drinking water bout (mg CrVI)
exceeding the empirically-based mouse stomach CrVI reducing
equivalent (mg CrVI) at water concentrations greater than 20 mg
CrVI/L (see Table 3 of Proctor et al., 2012), water concentrations
associated with at least minimal neoplastic effects in the mouse
small intestine in NTP (2008). Moreover, based on drinking water
mouse study data (e.g., histological, biochemical, toxicogenomic,
pharmacokinetic) collected speciﬁcally to assess the MOA in the
mouse small intestine in the context of regulatory agency MOA
frameworks, Thompson et al. (2013a) present a weight of evidence
in support of a cytotoxic MOA with the following key events:
 Absorption of CrVI from the intestinal lumen.
 Toxicity to intestinal villi.
 Crypt regenerative hyperplasia.
 Clonal expansion of mutations within the crypt stem cells,
resulting in late onset tumorigenesis.
Under relevant regulatory agency guidelines (e.g., TCEQ, 2012;
USEPA, 2005), low-dose extrapolation approaches (e.g., linear,
non-linear/threshold) are evaluated on an assessment-by-assess-
ment basis in the context of the relevant data available. For
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approach can be applied when consistent with the current under-
standing of the carcinogenic MOA. Carcinogenic MOA information
and data supporting mechanisms or key events expected to impart
a non-linear or threshold dose–response at low doses may sufﬁ-
ciently support considering (and ultimately adopting) carcinogenic
assessment approaches other than linear low-dose extrapolation.
This should be particularly true in cases when the resulting toxicity
factor will be used to assess low, environmentally-relevant oral
doses from a health perspective where based on available informa-
tion, non-linearity in response is expected. The data collected and
analyses conducted for the CrVI MOA research project (e.g.,
Thompson et al., 2013a) support consideration of a non-linear/
threshold carcinogenic assessment. Accordingly, in addition to a
linear low-dose extrapolation approach for CrVI-induced carcino-
genicity due to oral exposure, a non-linear/threshold approach will
be considered in this paper for its utility in the development of a
scientiﬁcally-defensible, cancer-based oral toxicity factor for CrVI.
These approaches will be evaluated in the context of analyses con-
ducted based on toxicokinetic information that reveal non-linear
relationships between applied oral and internal dose (e.g., Haney,
2015; Kirman et al., 2012), which should be taken into account
in dose–response assessment by assessing the potential for a
non-linear dose–response (USEPA, 2005).
2. Materials and methods
This paper considers two approaches for deriving a cancer-
based, chronic oral toxicity factor for CrVI. The linear low-dose
extrapolation method is exempliﬁed by the draft oral slope factor
(SFo) developed in USEPA (2010). The non-linear/threshold
approach considered is represented by the derivation of the refer-
ence dose (RfD) contained in Thompson et al. (2013b). While the
scientiﬁc debate on the overall weight of evidence for the most
likely and plausible MOA(s) continues in light of the recent MOA
research of the past few years, that debate is beyond the scope of
this paper. However, even outside of the MOA debate, some of
the data (e.g., toxicokinetic) collected in recent years have appar-
ent and signiﬁcant implications for the linear low-dose and non-
linear/threshold extrapolation approaches, which are the focus of
this paper.
More speciﬁcally, based on the target tissue data provided in
Kirman et al. (2012), there are dose-dependent differences in
absorption by mouse target tissues (duodenum, jejunum, and
ileum) that have important implications for the derivation of tox-
icity factors such as the draft SFo and the proposed RfD (USEPA,
2010; Thompson et al., 2013b). These differences are discussed
and quantiﬁed in Haney (2015), which provides a peer-reviewed
approach to calculate dose-speciﬁc SFo adjustment factors based
on these differences to more accurately estimate risk at a given
dose. That paper also provides several example adjustment factors
for the draft SFo to more accurately estimate risk at lower, more
environmentally-relevant doses (e.g., federal maximum contami-
nant level (MCL), 1/3 the MCL, measured drinking water concentra-
tions). The current paper:
 Highlights dose-dependent differences in target tissue absorp-
tion (e.g., changes in target tissue absorption per unit dose,
non-linearity of tissue concentration versus dose).
 Utilizes the approach published in Haney (2015) (accounting for
dose-dependent changes in absorption by target tissues) and
associated results (dose-speciﬁc SFo adjustment factors) to
explore some important implications for linear and non-lin-
ear/threshold approaches in development of a cancer-based oral
toxicity factor for CrVI. Considers the implications of dose-dependent target tissue
absorption to draw conclusions concerning the most appropri-
ate low-dose extrapolation approach for the oral carcinogenic
assessment of CrVI.
The implications considered include the extent to which these
dose-dependent changes in absorption are consistent with linear
and non-linear approaches. This can be assessed simply by exam-
ining the toxicokinetic relationship between target tissue absorp-
tion/concentration and dose across relevant doses (e.g., the
relationship is non-linear if target tissue absorption per unit dose
changes appreciably with dose, resulting in a departure from lin-
earity for tissue concentration versus dose). Another implication
of dose-dependent target tissue absorption considered is the mag-
nitude to which linear low-dose extrapolation is likely to overesti-
mate risk at lower, more environmentally-relevant CrVI doses. The
methods and dose-speciﬁc adjustment factors published in Haney
(2015) adjust for the extent to which linear low-dose extrapolation
(based on the draft SFo) overestimates target tissue absorption and
risk at a given dose. These adjustment factors provide dose-speciﬁc
estimates of risk overestimation by linear low-dose extrapolation
(i.e., the magnitude of departure from linearity) for the current
paper. In addition to being valuable in the consideration of the lin-
ear approach, they also provide the ability to better characterize
uncertainty when evaluating a non-linear/threshold approach
(see Section 3.2.2).
In considering the implications of dose-dependent absorption
for evaluating the defensibility of using a linear or non-linear/
threshold approach as the most appropriate basis for developing
a cancer-based oral toxicity factor for CrVI, an inherent assumption
is that any carcinogenic risk is a function of target tissue concen-
tration. This is common practice for regulatory risk assessment in
general and applies regardless of the carcinogenic MOA assumed
for CrVI (i.e., mutagenicity versus a threshold for regenerative
hyperplasia). Additionally, it appears to be valid in this speciﬁc
case based on Fig. 1, for example, which shows that the incidence
of adenoma/carcinoma in the mouse duodenum (Tables 5 and 6 of
NTP (2008)) appears related to the mouse duodenum tissue con-
centrations resulting from oral CrVI exposure (Table 8 of Kirman
et al. (2012)). Additional details are provided in the relevant sec-
tions below.3. Results and discussion
3.1. Consideration of linear low-dose extrapolation
An SFo is the toxicity factor that results from implementation of
the linear low-dose extrapolation approach for assessment of car-
cinogenicity due to oral exposure. The units for an SFo are risk per
unit oral dose, or more speciﬁcally in this case, excess risk per mg
CrVI/kg body weight-day. USEPA (2010) provides a draft SFo of 0.5
per mg/kg-day based on the incidence of neoplasms (i.e., adeno-
mas, carcinomas) in the mouse small intestine (primarily in the
duodenum and jejunum) in the National Toxicology Program
(NTP) mouse drinking water study (NTP, 2008).
The assumption inherent in using linear low-dose extrapolation
to derive an SFo (and in the SFo itself) is that risk is linearly related
to target tissue concentration (internal dose metric), and that the
toxicokinetic relationship between target tissue concentration
and oral dose is essentially the same (more-or-less constant) across
the doses for which the SFo will be used to estimate risk (e.g., there
are not appreciable dose-dependent changes in the dose fraction
absorbed by target tissues). That is, in assuming (as does the SFo)
that risk is linearly related to oral dose, it is assumed that an oral
Fig. 1. Duodenum tissue concentration and neoplasm incidence versus dose.
Table 1
Mouse target tissue absorption per unit dose.
Oral dosea
(mg CrVI/
kg-day)
Total Cr in
target
tissueb
(mg Cr)
Added Cr in
target tissue due
to dosec (mg Cr)
Target tissue absorption per
unit dosed (mg Cr in target
tissues/dose in mg CrVI/kg-
day)
0 3.34E05 – –
0.024e 3.89E05 5.48E06 2.28E04
0.32 5.33E04 4.99E04 1.56E03
1.1f 2.51E03 2.47E03 2.25E03
4.6 1.28E02 1.28E02 2.78E03
a From Table 1 of Haney (2015), based on Table 3 of Kirman et al. (2012).
b Based on the sum of total Cr (mg) in the three mouse target tissues (duodenum,
jejunum, and ileum) from Tables 3–5 of Haney (2015).
c Added mg Cr due to a given CrVI dose equals the total mg Cr in target tissues
minus the background mg Cr in tissues at 0 dose (3.34E05 mg Cr as shown above).
d Calculated as the added Cr (mg) in target tissue (duodenum, jejunum, and
ileum)/oral dose (mg CrVI/kg-day).
e Dose at the federal MCL of 0.1 mg Cr/L.
f Dose at the POD used for the draft SFo (BMDL10 values of 1.0–1.2 mg/kg-day).
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dose results in half the target tissue concentration and so on, main-
taining linearity between oral dose and risk so that the SFo is rea-
sonably predictive of risk at the doses (most often environmental)
being evaluated. However, if target tissue concentration (and
therefore risk) is not linearly related to oral dose (e.g., due to
dose-dependent changes in absorption), then the SFo may signiﬁ-
cantly overestimate or underestimate risk at doses of interest as
it uses oral dose to estimate risk. For an SFo to reliably predict risk
with reasonable accuracy at lower, environmentally-relevant
doses, the oral dose should be linearly related to target tissue con-
centration as the internal dose metric and determinant of risk
across relevant doses. That is, for example, appreciable dose-de-
pendent differences in the dose fraction absorbed by target tissues
should not exist between the SFo point of departure (POD) dose
and truly environmentally-relevant doses where the SFo will be
used to estimate risk. This leads to the ﬁrst and most critical ques-
tion for consideration in this paper.
3.1.1. Is target tissue CrVI absorption/concentration low-dose linear?
A recent study (Haney, 2015) highlights that there are signiﬁ-
cant dose-dependent differences in the dose fraction absorbed by
mouse target tissues for which the draft SFo would need to be
adjusted. For example, based on the analysis of target tissue con-
centrations (Kirman et al., 2012) in Haney (2015), estimates of
the differences in the dose fractions absorbed by target tissues at
truly environmentally-relevant water concentrations compared
to the POD dose used to derive the draft SFo are signiﬁcant. The
estimated dose fraction absorbed at the 35-city drinking water
geometric mean (GM of 0.00018 mg/L) reported in EWG (2010) is
over 2400 times lower than that calculated for the draft SFo POD.
Even for the city with the highest drinking water concentration
(0.0129 mg/L) reported in EWG (2010), the estimate of the dose
fraction absorbed is over 30 times lower than that calculated for
the draft SFo POD dose. In other words, based on these and other
dose-dependent changes in absorption discussed in Haney(2015), the toxicokinetic relationship between target tissue con-
centration and oral dose varies signiﬁcantly (i.e., is far from being
more-or-less constant) across the doses for which the draft SFo
would be used (if adopted) to estimate risk compared to that at
the POD dose used to derive the SFo (for this reason, Haney
(2015) calculates corresponding dose-speciﬁc adjustment factors
for the draft SFo).
As an example for the current paper, based on data in Table 1,
Fig. 2 shows target tissue absorption per unit dose CrVI (i.e., added
mg Cr in target tissue per mg CrVI/kg-day oral exposure) from 0 to
4.6 mg CrVI/kg-day, which covers doses of interest (e.g.,
0.024 mg CrVI/kg-day at the federal MCL, 1.1 mg CrVI/kg-day at
draft SFo POD). Clearly, target tissue absorption per unit dose
changes appreciably with dose and is not the same at the draft
SFo POD dose as it is at the much lower doses for which the SFo
would be used to estimate risk. More speciﬁcally, as doses decrease
from the POD dose, target tissue absorption per unit dose
Fig. 2. Mouse target tissue absorption per unit dose and tissue concentration versus dose.
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the competing rates of reduction/detoxiﬁcation prior to CrVI
absorption by target tissues or other factors). For example, target
tissue absorption per unit dose is an estimated 10-fold lower at
the dose corresponding to federal MCL than at the SFo POD dose
used for linear low-dose extrapolation (Fig. 2). If the toxicokinetic
relationship between target tissue concentration and dose was the
same across doses, the slope of the target tissue absorption per unit
dose line in Fig. 2 would essentially be zero (i.e., the line would be
horizontal or close to it) and a plot of target tissue concentration
versus dose would be linear, all the way down to zero dose.
However, the differences in target tissue absorption per unit dose
shown in Fig. 2 at lower doses compared to higher doses (e.g.,
the draft SFo POD dose) indicate that target tissue concentration
versus dose should be expected to depart from linearity, which
in fact is shown in Fig. 2 as well (see below).
Based on data in Table 2, Fig. 2 shows tissue concentration due
to CrVI exposure (added mg Cr/kg tissue on the second y-axis) ver-
sus dose for the three mouse target tissues (duodenum, jejunum,
and ileum). Additionally, the low-dose magniﬁed view (right side
of Fig. 2) shows linear low-dose extrapolations of duodenum and
jejunum tissue concentrations from those measured at the draft
SFo POD dose (the extrapolated linear low-dose line for ileum tis-
sue concentration was not shown as it would have obscured the
jejunum actual tissue concentration line, but similar to other tis-
sues the extrapolated line was noted to fall above the actual ileum
tissue concentration line). Note that the mouse dose at the federalTable 2
Target tissue concentrations due to oral CrVI exposure.
Oral dose
(mg CrVI/
kg-day)
Added Cr in
duodenum tissue
due to dosea (mg Cr/
kg tissue)
Added Cr in
jejunum tissue due
to dosea (mg Cr/kg
tissue)
Added Cr in ileum
tissue due to dosea
(mg Cr/kg tissue)
0 0 0 0
0.008 9.00E03 0 0
0.024 3.90E02 0 0
0.32 1.50E+00 6.80E02 2.10E02
1.1b 7.20E+00 2.80E01 1.10E01
4.6 3.35E+01 4.70E+00 9.00E01
a From Table 8 of Kirman et al. (2012) for the highest four doses and controls and
from Tables 7 and 8 of Haney (2015) for the lowest dose; added mg Cr/kg tissue due
to a given CrVI dose equals the total mg Cr/kg tissue at that dose minus the
background mg Cr/kg tissue at 0 dose.
b Dose at the POD used for the draft SFo (BMDL10 values of 1.0–1.2 mg/kg-day);
associated tissue concentrations were used for low-dose extrapolation of the target
tissue concentrations predicted by linear low-dose extrapolation.MCL (0.024 mg/kg-day) falls at the middle of the dose axis in the
low-dose magniﬁed view, and environmentally-relevant doses
are even lower (EWG, 2010). As expected based on the dose-de-
pendency of target tissue absorption per unit dose and the reduced
absorption at lower doses in particular, target tissue concentra-
tions depart from those expected based on low-dose linearity
(i.e., linear low-dose extrapolation from those at the SFo POD dose)
(see low-dose magniﬁed view of Fig. 2). This is true for all three
target tissues. However, this is of particular concern for the duode-
num as the target tissue where most of the adenomas/carcinomas
occurred in NTP (2008), and therefore the principal contributor to
the draft SFo. Contrary to the assumption of low-dose linearity
inherent in use of an SFo, consistent with the target tissue absorp-
tion evidence presented above, these tissue concentration data
indicate that tissue concentration (and therefore any risk) should
not be expected to be low-dose linear across relevant doses (e.g.,
doses 6 the SFo POD dose) but rather non-linear (i.e., sub-linear).3.1.2. Does linear low-dose extrapolation appreciably overestimate
risk at lower, more environmentally-relevant CrVI doses?
In conjunction with evaluating dose-dependent changes in the
dose fraction absorbed by target tissues, the Haney (2015) study
provides a straightforward, peer-reviewed method to account for
this toxicokinetic phenomenon. The approach requires dividing
the draft SFo by a dose-speciﬁc adjustment factor to make it more
predictive of risk at the lower, more environmentally-relevant
dose. The dose-speciﬁc SFo adjustment factor accounts for the dif-
ference in the dose fraction absorbed at the draft SFo POD dose
compared to that at the dose being used to estimate risk. As such,
it is an estimate of the magnitude of risk overestimation by linear
low-dose extrapolation when using the draft SFo.
Table 3 provides dose-speciﬁc adjustment factors for the draft
SFo at various doses evaluated in Haney (2015). Considering the
data presented in Fig. 2 (e.g., signiﬁcant dose-dependent differ-
ences in target tissue absorption per unit dose), it is not surprising
that these SFo adjustment factor values vary widely with dose. The
greater the difference in dose from the draft SFo POD dose, the
more that linear low-dose extrapolation from the POD appears to
overestimate risk. For example, the SFo adjustment factors for
the federal MCL (0.1 mg/L), along with the highest city drinking
water concentration (0.0129 mg/L) and 35-city geometric mean
(GM of 0.00018 mg/L) reported in EWG (2010), are 4.3, 34, and
2,408, respectively (Table 3). This wide range of adjustment factors
for environmentally-relevant doses (i.e., doses corresponding to
water concentrations  the federal MCL) strongly suggests that
Table 3
Risk estimates using the draft SFo adjusted for dose-dependent differences in the dose fraction absorbed by target tissues.
Mouse dosea (mg/kg-day) (water concentration) SFo adjustment factorb Human equivalent dosec (mg/kg/day) Excess risk with adjusted SFod
4.3E05 (35-city GM of 0.00018 mg/L) 2.408 7.1E06 1.5E09
3.1E03 (highest city 0.0129 mg/L) 34 5.1E04 7.9E06
8.0E03 (1/3 MCL 0.0333 mg/L) 6.2 1.3E03 1.1E04
2.4E02 (MCL 0.1 mg/L) 4.3 3.9E03 4.7E04
1.165E+00 (male mouse POD/BMDL10) 1 1.9E01 1.0E01
a Doses at MCL and 1/3 MCL from Table 9 of Haney (2015), lower doses based on ratio of water concentration to MCL  dose at MCL; BMDL10 from USEPA (2010).
b From Table 9 or text of Haney (2015).
c Human dose = mouse dose/(70 kg/0.05 kg)0.25.
d Adjusted risk based on unrounded SFo of 0.525 per mg/kg-day (i.e., 0.1 risk/human dose of 0.1905)  human equivalent dose/SFo adjustment factor.
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sonably predict risk across the range of doses for which it would be
used to estimate risk, as the magnitude of risk overestimation due
to differences in dose-dependent absorption varies signiﬁcantly
across relevant doses.
Based on the data in Table 3, Fig. 3 illustrates the appreciable
disparity between risk estimated by linear low-dose extrapolation
through use of the draft SFo compared to risk estimates that
account for the much lower dose fractions absorbed at these lower,
more environmentally-relevant doses. Similar to the cross-species
extrapolation of the draft SFo by USEPA (2010), the mouse dose
data in Table 3 were extrapolated to humans with body weight
scaling. Cross-species extrapolation of animal data to humans is
required for the CrVI oral carcinogenic assessment as there are
no adequate human studies. Therefore, the risk estimates shown
in Fig. 3 are for humans. Fig. 3 is similar to Fig. 3–1 from USEPA
(2005), reproduced herein as Fig. 4, which USEPA uses to caution
against selecting a POD for calculation of an SFo that fails to reﬂect
the shape of the dose–response curve at lower doses as this intro-
duces bias. Based on the evidence presented above and depicted in
Fig. 3 (as well as Fig. 2), the bias in this case is appreciable overes-
timation of risk by linear low-dose extrapolation.
3.2. Consideration of the non-linear/threshold approach
Data from the CrVI MOA research project (e.g., Thompson et al.,
2011a) have provided support for considering a non-linear/Fig. 3. Excess risk vethreshold approach. Consequently, Thompson et al. (2013b)
derives an RfD to protect against the proposed carcinogenic MOA
key event of intestinal diffuse hyperplasia as a precursor effect to
tumor formation. The study authors suggest that the proposed
RfD (0.006 mg/kg-day) is protective of both noncancer and cancer
effects. As with linear low-dose extrapolation, this approach is now
considered in light of dose-dependent changes in absorption by
mouse target tissues (duodenum, jejunum, and ileum).
3.2.1. Target tissue CrVI absorption/concentration and risk are non-
linear
Evidence that target tissue absorption/concentration (and
therefore risk) depart from linearity (i.e., are non-linear) across rel-
evant doses has already been presented (Section 3.1), so will be
only brieﬂy discussed here. As can be seen from examination of
Fig. 2 (low-dose magniﬁed view), the absorption of CrVI into target
tissues is non-linear from relatively higher doses (e.g., draft SFo
POD dose) to lower, more environmentally-relevant doses. This is
because the CrVI absorbed by target tissues per unit dose (or dose
fraction absorbed as discussed in Haney (2015)) progressively
decreases with decreasing dose, resulting in sub-linearity. This is
the case for all three target tissues (duodenum, jejunum, and
ileum). As a result, when this is taken into account and adjusted
for, estimated risk becomes increasingly non-linear (i.e., increas-
ingly departs from the low-dose linear SFo prediction) as doses
decrease compared to linear low-dose extrapolation from the draft
SFo POD (Fig. 3).rsus lower dose.
Fig. 4. Compatibility of alternate points of departure with observed and modeled tumor incidence (USEPA, 2005).
Fig. 5. RfD approach for a threshold MOA.
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from CrVI oral exposure toxicokinetics strongly suggests that
some type of approach and toxicity factor that are consistent
with non-linearity in response at lower doses are most appropri-
ate and defensible. Although this non-linearity does not address
the potential for existence of a threshold for CrVI-induced car-
cinogenic effects due to oral exposure (see Thompson et al.,
2013b), which is outside the scope of this paper, it is noted that
a threshold approach (Fig. 5, adapted from TCEQ (2012)) is com-
monly used for effects with a dose–response that deviates from
linearity (e.g., see dose–response curves for hyperplasia as a pro-
posed carcinogenic MOA key event in Figs. 1A, 3, 4A, and 5 of
Thompson et al. (2013b)). Importantly, the resulting toxicity fac-
tor (e.g., RfD) does not assume low-dose linearity, an assumption
that would be inconsistent with dose-dependent changes in tar-
get tissue absorption at the SFo POD dose compared to that at
lower, more environmentally-relevant doses (see Fig. 2 and
Haney, 2015).3.2.2. What risk may potentially be associated with a non-linear/
threshold approach?
The ability to better characterize uncertainty is another impor-
tant use of the dose-speciﬁc SFo adjustment factors published in
Haney (2015) when evaluating a non-linear/threshold approach.
More speciﬁcally, although there are data providing support for a
non-linear/threshold approach (e.g., Thompson et al., 2011a), con-
sideration of dose-dependent differences in the dose fraction
absorbed through use of calculated adjustment factors for the draft
SFo allows better estimates of the risk that could be associated
with a given RfD in the event that a weight of evidence ﬁnding
for a non-mutagenic MOA were incorrect. For example, an RfD
(0.006 mg/kg-day) has been proposed by Thompson et al.
(2013b) based on a weight of evidence in support of a cytotoxic
(i.e., non-mutagenic) MOA (Thompson et al., 2013a), benchmark
dose analyses, and physiologically-based toxicokinetic (PBTK)
modeling. This RfD corresponds to a mouse dose of approximately
0.037 mg/kg-day (mouse dose = human dose  (70 kg/0.05 kg)0.25).
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jejunum, and ileum) concentrations, the total dose fraction
expected to be absorbed by target tissues at this dose, and ulti-
mately the dose-speciﬁc SFo adjustment factor per the methodol-
ogy published in Haney (2015). The resulting dose-speciﬁc
adjustment factor for the draft SFo is 3.7 (calculations not shown).
Using this factor to adjust the draft SFo (0.5 per mg/kg-day/
3.7  0.14 per mg/kg-day) and estimate potential risk at this pro-
posed RfD results in an estimate of approximately 8E04. Note
that this assumes (for the sake of argument) that a mutagenic
MOA is operating while based on data collected for the CrVI MOA
research project, actual risk at this dose could be as low as zero
(Thompson et al., 2013b).
A potential RfD of 0.003 mg/kg-day is also considered here as
this human intake corresponds approximately to the MCL
(0.1 mg/L). The potential RfD of 0.003 mg/kg-day corresponds to
a mouse dose of approximately 0.018 mg/kg-day (mouse dose =
human dose  (70 kg/0.05 kg)0.25), which is similar to the mouse
dose at the MCL (0.024 mg/kg-day) reported in Kirman et al.
(2012). This mouse dose falls in the middle of two mouse doses
evaluated in Haney (2015) (0.012 and 0.024 mg/kg-day). Based
on Table 9 of that study, the adjustment factor for the draft SFo
based on the mouse dose of 0.024 mg/kg-day is 4.3, while the
SFo adjustment factor at 0.012 mg/kg-day would be 5.5 (i.e.,
three-target tissue mean dose fraction absorbed of 8.55E02/
1.55E02). Given these two adjustment factors, it is not surprising
that use of the method published in Haney (2015) for a mouse dose
of 0.018 mg/kg-day results in an adjustment factor for the draft SFo
of 4.8 (calculations not shown). Appropriately adjusting the draft
SFo by this factor (0.5 per mg/kg-day/4.8  0.10 per mg/kg-day)
to estimate potential risk at this MCL-based human intake
(0.003 mg/kg-day) results in an estimate of approximately
3E04. If the draft SFo had been based on the benchmark dose
(BMD10) rather than the 95% lower conﬁdence limit (BMDL10),
use of the adjusted SFo (0.28 per mg/kg-day/4.8  0.06 per mg/
kg-day) for this intake would result in an estimate of potential risk
of approximately 1.8E04. Again, this assumes a mutagenic MOA
is actually operating while based on data collected for the CrVI
MOA research project, actual risk at this dose could be as low as
zero.
Accordingly, in addition to supporting a non-linear approach,
appropriate consideration of dose-dependent changes in absorp-
tion by target tissues has important implications for the evaluation
of adopting a threshold approach (e.g., the RfD derived in
Thompson et al. (2013b)). Most speciﬁcally, it allows for a better
characterization of the uncertainty associated with the adoption
of a threshold approach, that is, a better quantitative estimate of
the potential risk associated with drawing an incorrect MOA con-
clusion. Results indicate that despite the data which support a
non-mutagenic MOA, if the MOA was assumed to be mutagenic,
estimates of the potential risk associated with an MCL-based RfD
(excess risk of 1.8E04 to 3E04) would be near the upper end
of the USEPA acceptable risk range (1E04) and lower than the risk
associated with the arsenic federal MCL (excess risk of 5E04 at
10 ppb based on the USEPA IRIS drinking water unit risk of
5E05 per ppb).4. Conclusions
The dose-dependent changes in absorption by mouse target tis-
sues have important implications for the potential use of linear and
non-linear/threshold approaches in development of a cancer-based
oral toxicity factor for CrVI. More speciﬁcally, the decreasing target
tissue absorption per unit dose (or decreasing dose fractions
absorbed as discussed in Haney (2015)) as doses decrease to lower,more environmentally-relevant doses are inconsistent with linear
low-dose extrapolation but consistent with a non-linear approach.
Risk should not be linearly related to oral CrVI dose due to appre-
ciable dose-dependent differences in target tissue absorption
across relevant doses that result in non-linearity between oral dose
and target tissue concentration. This is the case regardless of
whether the carcinogenic MOA is non-mutagenic or mutagenic. If
concluded to be non-mutagenic based on relevant data generated
for the CrVI MOA project (e.g., Thompson et al., 2013a), then a
non-linear (i.e., threshold) dose–response would be expected. On
the other hand, if a mutagenic MOA is assumed, since risk is a func-
tion of tissue concentration and target tissue concentration is non-
linear with dose from higher to lower and more relevant doses, it
follows that a non-linear dose–response would still be expected
(i.e., a non-linear/sub-linear dose–response down to zero dose).
This is illustrated by Fig. 3, which shows the appreciable disparity
between human risk estimated by a linear low-dose approach (i.e.,
the draft SFo) compared to risk estimates that account for the
much lower dose fractions absorbed at lower doses. Thus, even
assuming for the sake of argument that risk is linearly related to
target tissue concentration in the low-dose region (i.e., even with-
out consideration of a weight of evidence for a cytotoxic/threshold
MOA), the shape of the oral dose–response curve that accounts for
this toxicokinetic phenomenon is clearly non-linear (i.e., sub-
linear).
Moreover, as discussed earlier and presented in Table 3, the cal-
culated adjustment factors that would be necessary to more accu-
rately estimate risk at environmentally-relevant doses using the
draft SFo (i.e., assuming low-dose linearity between target tissue
concentration and risk) vary dramatically and are higher at lower
doses. This indicates that the magnitude of risk overestimation
by a linear low-dose extrapolation approach (the draft SFo in this
case) increases as it is used to predict risk at lower, more environ-
mentally-relevant doses where the dose fractions absorbed by tar-
get tissues progressively decrease at lower and lower doses (note
that the magnitude of risk overestimation would be exacerbated
if a threshold MOA were operating). Furthermore, it demonstrates
that no single adjustment factor can be calculated for the linear
low-dose SFo approach to predict risk reasonably well across
potential environmental doses as the adjustment factors are
dose-speciﬁc and span orders of magnitude. By corollary, no single
SFo can be used to reliably predict risk across potential environ-
mental doses (e.g., from the MCL down to the 35-city GM; the draft
SFo appears to only reliably predict risk at the POD used to derive
it). This appears to preclude adoption of an SFo for CrVI-induced
carcinogenesis, thereby making adoption of a linear low-dose
extrapolation approach untenable. Therefore, for reasons cited in
this and the preceding paragraph, it is concluded that a non-linear
approach is most scientiﬁcally defensible for derivation of an oral
toxicity factor for CrVI-induced carcinogenesis.
Derivation of an RfD is a non-linear approach that has already
been implemented for CrVI-induced carcinogenesis in the peer-re-
viewed, scientiﬁc literature (Thompson et al., 2013b). An RfD
approach assumes, however, that a threshold exists for the critical
effect (CrVI-induced carcinogenesis in this case). Consequently,
data relevant to the MOA which inform the potential for a thresh-
old should be evaluated by regulatory agencies as biology (i.e., bio-
logical mechanisms as opposed to default modeling exercises)
underlies and drives any actual chemical risk, and generally robust
and redundant biological homeostatic mechanisms form the foun-
dation of toxicity thresholds (Rhomberg et al., 2011). Such data
have been speciﬁcally collected for the CrVI MOA research project
and clearly should be duly considered by regulatory agencies in
chemical assessment to inform the MOA (e.g., key events) and bio-
logically-plausible expectations about potential thresholds and any
low-dose risk. Failure of a chemical assessment’s low-dose
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and scientiﬁcally defensible) available data (e.g., MOA, toxicoki-
netic) may result in signiﬁcantly overestimating environmental
risk (Fig. 3). It is further concluded that a non-linear/threshold car-
cinogenic assessment approach (i.e., RfD) may be more scientiﬁ-
cally defensible than the alternative (i.e., default linear low-dose
extrapolation) considering:
 Signiﬁcant non-linearity in response is expected across lower,
more environmentally-relevant oral doses based on toxicoki-
netic analyses discussed in the current study and Haney (2015).
 Low-dose extrapolation approaches are considered and adopted
on an assessment-by-assessment basis in the context of the
available data (TCEQ, 2012; USEPA, 2005).
 Analysis of data collected for the CrVI MOA research project are
supportive of a cytotoxic/threshold MOA for CrVI-induced car-
cinogenicity due to oral exposure (e.g., Thompson et al., 2013a).
 USEPA indicates that an RfD should be developed when tumors
arise through a non-linear MOA (see page 3–24 of USEPA
(2005)).
Lastly, another important implication of the analysis of dose-
dependent changes in target tissue absorption when evaluating a
non-linear/threshold approach is the ability to better characterize
uncertainty. That is, it allows better estimates of the risk that could
be associated with a given RfD in the event that a weight of evi-
dence ﬁnding for a non-mutagenic MOA were incorrect. Results
indicate that even if the MOA was assumed to be mutagenic, esti-
mates of the potential risk associated with an MCL-based RfD
(excess risk of 1.8E04 to 3E04) would be near the upper end
of the USEPA acceptable risk range and lower than the risk associ-
ated with the arsenic federal MCL (excess risk of 5E04 at 10 ppb),
which may be deemed acceptable. Lower potential risk estimates
may result from use of the rodent and human PBTK models
(Kirman et al., 2012, 2013) to extrapolate potential draft SFo mouse
POD doses (BMD10/BMDL10) to humans (in lieu of the default body
weight scaling conducted by USEPA (2010)) in order to calculate a
revised draft SFo prior to applying the adjustment factors in
Table 3. However, it is also noted that actual risk at the dose asso-
ciated with the MCL (or a higher dose) could be as low as zero
based on a cytotoxic/threshold MOA (Thompson et al., 2013b).5. Uncertainties
As acknowledged by USEPA, extrapolation of experimental ani-
mal data to estimate potential human cancer risk yields uncer-
tainty. It is unknown how well linear low-dose extrapolation
predicts low-dose risks for CrVI (USEPA, 2010). Consequently, like
other studies which extrapolate laboratory animal data using this
approach to estimate human risk, this is an area of uncertainty
for the portions of the current study which estimate potential
human risk based on animal data (NTP, 2008; Kirman et al.,
2012). Although the risk estimate examples contained in the pre-
sent study assume low-dose linearity of target tissue dose (not oral
dose) and risk (i.e., a mutagenic MOA), this paper should not be
viewed as an endorsement of it in the ongoing MOA debate, as this
approach may not be the best supported low-dose extrapolation
method for CrVI oral risk assessment (e.g., evaluating environmen-
tal doses) based on the MOA information available for CrVI-in-
duced oral carcinogenicity (e.g., Thompson et al., 2011a, 2013a).
Rather than mechanisms, this paper speciﬁcally focuses on the
implications of dose-dependent changes in target tissue absorption
(i.e., the high-to-low-dose toxicokinetics of absorption by the
mouse small intestine). While this limited focus may be viewed
as a study limitation, it would appear that dose-dependent changesin absorption and the resulting non-linearity in target tissue con-
centration versus dose strongly support that the expected dose–
response should be non-linear in nature. Beyond this, the uncer-
tainties associated with this assessment are the same as those
associated with the toxicokinetic (i.e., dose-dependent, dose frac-
tion absorbed) analyses conducted in the Haney (2015) peer-re-
viewed publication. Readers are referred to that published, open
access study as well as USEPA (2010) for additional discussion of
associated uncertainties.
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